Recently, roscovitine was tested in the CF population in a Phase 2A trial 16 (ROSCO-CF: A Phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of [R]-roscovitine in adults subjects with CF, with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa). This evidence concerns the gene CFTR and cystic fibrosis.